Acute Heart FailurePhase 2COMPOSE 1NCT01065077
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A Phase 2 study testing Cinaciguat (BAY58-2667) in people with Acute Heart Failure, run by Bayer at 59 sites in 17 countries.
Trial summary
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Heart Failure
- What is being tested?
- Cinaciguat (BAY58-2667)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 59 sitesin 17 countries
- Study dates
- Mar 2010to Feb 2011
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or women without childbearing potential defined as postmenopausal women aged 55 years or older, women with bilateral tubal ligation, women with bilateral ovariectomy, and women with a hysterectomy
- Subjects must have the clinical diagnosis of CHF made at least three months prior to enrollment
- Subjects must experience worsening of both of the symptoms below leading to hospitalization at the time of entry into the study:
- dyspnea and
- clinical evidence of volume overload
Who cannot join
- Acute de-novo heart failure
- Acute myocardial infarction and/or myocardial infarction within 30 days
- Valvular heart disease requiring surgical intervention during the course of the study
- Heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease
- Primary hypertrophic cardiomyopathy
- Acute inflammatory heart disease, eg, acute myocarditis
- Unstable angina requiring angiography
Trial locations and contacts
59 sites in 17 countries.
59 sites in 17 countries
Japan8 sites
Study site
Bunkyo-ku, Tokyo, 113-8603
Study site
Higashiibaraki, Ibaraki, 311-3193
Study site
Kawasaki, Kanagawa, 216-8511
Study site
Kure, Hiroshima, 737-0023
Study site
Nagoya, Aichi-ken, 460-0001
Study site
Ōmura, Nagasaki, 856-8562
Study site
Osaka, Osaka, 543-0035
Study site
Shinagawa, Tokyo, 142-8666
Poland7 sites
Study site
Gdansk, 80-211
Study site
Lodz, 91-347
Study site
Warsaw, 02-507
Study site
Warsaw, 04-628
Study site
Wroclaw, 50-981
Study site
Zabrze, 41-800
Study site
Zgorzelec, 59-900
United States6 sites
Study site
Cleveland, Ohio, 44106
Study site
Fairfield, Ohio, 45014
Study site
Philadelphia, Pennsylvania, 19102
Study site
Philadelphia, Pennsylvania, 19107
Study site
Ridgewood, New Jersey, 07450
Study site
Winston-Salem, North Carolina, 27157
Germany5 sites
Study site
Cologne, North Rhine-Westphalia, 50924
Study site
Erfurt, Thuringia, 99089
Study site
Greifswald, Mecklenburg-Vorpommern, 17475
Study site
Homburg, Saarland, 66424
Study site
Jena, Thuringia, 07740
Italy5 sites
Study site
Brescia, 25100
Study site
Ferrara, 44100
Study site
Mantua, 46100
Study site
San Fermo della Battaglia, Como, 22020
Study site
Torino, 10126
Russia4 sites
Study site
Krasnoyarsk, 660022
Study site
Moscow, 109263
Study site
Moscow, 115093
Study site
Moscow, 119881
Israel3 sites
Study site
Haifa, Israel, 34362
Study site
Jerusalem, Israel, 91120
Study site
Tiberias, Israel, 31905
Serbia3 sites
Study site
Belgrade, 11000
Study site
Kamenitz, 21204
Study site
Niš, 18000
Slovenia3 sites
Study site
Celje, 3000
Study site
Golnik, 4204
Study site
Ljubljana, 1000
Austria2 sites
Study site
Linz, Upper Austria, 4010
Study site
Vienna, State of Vienna, 1090
Switzerland2 sites
Study site
Lugano, Canton Ticino, 6900
Study site
Zurich, Canton of Zurich, 8091
About this study
Official title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
- Conditions
- Acute Heart Failure
- Being tested
- Cinaciguat (BAY58-2667), Placebo
- Keywords
- Heart Failure
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cinaciguat (BAY58-2667)Drug
Infusion of 150 µg/h during 48h
Cinaciguat (BAY58-2667)Drug
Infusion of 100 µg/h during 48h
Cinaciguat (BAY58-2667)Drug
Infusion of 50 µg/h during 48h
PlaceboDrug
Infusion of placebo during 48h
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Experimental | Not described Receives: Drug: Cinaciguat (BAY58-2667) |
| Arm 2 | Experimental | Not described Receives: Drug: Cinaciguat (BAY58-2667) |
| Arm 3 | Experimental | Not described Receives: Drug: Cinaciguat (BAY58-2667) |
| Arm 4 | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pulmonary Capillary Wedge Pressure
Measured: 8 hours
Secondary outcomes (3)
Cardiac index (CI)
Measured: 8 hours and 48 hours
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Measured: Follow up (30 + 5 days)
Right atrial pressure (RAP)
Measured: 8 hours and 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2010 (estimated)
- Study startMar 2010
- Primary completionJan 2011
- Study completionFeb 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Heart FailureStudies of the same condition, open and under way.
- More trials run by BayerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bayer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bayer Study Director, Study director, Bayer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01065077
- Sponsor's protocol ID
- 14560
- Other IDs
- 2009-014377-40, 2009
- Acronym
- COMPOSE 1
- Status last verified
- Nov 2014
- First submitted
- 8 Feb 2010
- Last updated
- 8 Oct 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A; COMPOSE Investigators and Coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail. 2012 Sep;14(9):1056-66. doi: 10.1093/eurjhf/hfs093. Epub 2012 Jun 19.
PubMed 22713287
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
- ClinicalTrials.gov ID
- NCT01065077
- Acronym / sponsor ID
- COMPOSE 1 / 14560
- Conditions
- Acute Heart Failure
- Keywords
- Heart Failure
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 12 participants (actual)
- Lead sponsor
- BayerIndustry (pharma, biotech, devices)
- Study start
- Mar 2010
- Primary completion
- Jan 2011 (actual)
- Study completion
- Feb 2011 (actual)
- First posted
- 9 Feb 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Experimental | Drug: Cinaciguat (BAY58-2667) |
| Arm 2 | Experimental | Drug: Cinaciguat (BAY58-2667) |
| Arm 3 | Experimental | Drug: Cinaciguat (BAY58-2667) |
| Arm 4 | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male and non-pregnant, non-lactating female subjects, age >/= 18 years of age; or women without childbearing potential defined as postmenopausal women aged 55 years or older, women with bilateral tubal ligation, women with bilateral ovariectomy, and women with a hysterectomy
- Subjects must have the clinical diagnosis of CHF made at least three months prior to enrollment
- Subjects must experience worsening of both of the symptoms below leading to hospitalization at the time of entry into the study:
Key exclusion criteria (7 listed)
- Acute de-novo heart failure
- Acute myocardial infarction and/or myocardial infarction within 30 days
- Valvular heart disease requiring surgical intervention during the course of the study
- Heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease
- Primary hypertrophic cardiomyopathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cinaciguat (BAY58-2667)Infusion of 150 µg/h during 48h | Drug | Arm 1 |
| Cinaciguat (BAY58-2667)Infusion of 100 µg/h during 48h | Drug | Arm 2 |
| Cinaciguat (BAY58-2667)Infusion of 50 µg/h during 48h | Drug | Arm 3 |
| PlaceboInfusion of placebo during 48h | Drug | Arm 4 |
Primary outcome
Pulmonary Capillary Wedge Pressure
Time frame: 8 hours
3 secondary outcomes
Cardiac index (CI)
Time frame: 8 hours and 48 hours
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time frame: Follow up (30 + 5 days)
Right atrial pressure (RAP)
Time frame: 8 hours and 48 hours
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2015.
- Results publication: PubMed 22713287Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A; COMPOSE Investigators and Coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail. 2012 Sep;14(9):1056-66. doi: 10.1093/eurjhf/hfs093. Epub 2012 Jun 19.
- Click here to find information about studies related to Bayer Healthcare products conducted in EuropeLink provided by the sponsor.
Related trials for Acute Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life
Heart Failure With Preserved Ejection Fraction, Iron Deficiencies
Not yet recruitingPhase 3
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure
Heart Failure, Acute Decompensated Heart Failure
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bayer Study Director study director
Bayer
59 sites in 17 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Cinaciguat (BAY58-2667) in people with Acute Heart Failure, run by Bayer at 59 sites in 17 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 8 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 59 sites in Japan, Poland, United States, Germany, Italy and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pulmonary Capillary Wedge Pressure (time frame: 8 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01065077, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2015.